Wednesday, January 2, 2019
Genomic Health initiated at Needham
Genomic Health initiated at Needham Genomic Health initiated with a Strong Buy at Needham. analyst Stephen Unger initiated Genomic Health with a Strong Buy rating and $86 price target, stating that he sees significant EPS upside potential from the commercialization of its expanding portfolio of molecular diagnostic testing services and a focus on profits.
https://thefly.com/landingPageNews.php?id=2842783
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.